Results 241 to 250 of about 114,789,047 (289)

Botulinum toxin in tension-type headache

Journal of Neurology, 2004
Despite the controversy regarding specific mechanism of botulinum toxin action in pain relief, clinical results suggest that botulinum toxin type A may be promising treatment options for patients with primary chronic headache. To investigate this, we included sixteen patients with chronic tension-type headache in a prospective double blind, placebo ...
Telarović, Srđana, Relja, Maja
openaire   +6 more sources

Botulinum Toxin Type B for Dynamic Glabellar Rhytides Refractory to Botulinum Toxin Type A

Dermatologic Surgery, 2003
Botulinum toxin type B (BTX-B; Myobloc) has recently been introduced for the treatment of dynamic rhytides. This serotype is structurally similar to botulinum toxin type A (BTX-A; Botox) and appears to produce equivalent muscular paralysis. Because of the fact that some patients may become resistant to the effects of BTX-A with its continued use or may
Tina S, Alster, Jason R, Lupton
openaire   +2 more sources

Botulinum Toxin Type B

Dermatologic Surgery, 2003
Botulinum toxin B is an antigenically distinct form of Botulinum toxin which has unique physical and clinical properties that distinguish it from Botulinum toxin A.To describe properties of Botulinum toxin B.More rapid onset, greater diffusion characteristics as well as diminished longevity have been identified to date in previous studies.BTX-B is safe
openaire   +2 more sources

Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure

Journal of Neurology, 2003
Recently, it was reported that botulinum toxin type B complex (BoNT/B) (NeuroBloc(R), Elan Pharmaceuticals) can produce an adequate therapeutic response in patients with antibody induced failure of botulinum toxin type A complex (BoNT/A) therapy. We wanted to study whether this effect is transient or sustained.
Dirk, Dressler, Hans, Bigalke, Reiner, Benecke   +2 more
openaire   +2 more sources

Molecular Weight of Type A Botulinum Toxin

Infection and Immunity, 1970
Clostridium botulinum type A does not produce a 12,000 molecular weight toxin. The reported isolation of such a material by Gerwing et al. could not be confirmed.
J N, Knox, W P, Brown, L, Spero
openaire   +2 more sources

Botulinum Toxin Type B (Myobloc)

Dermatologic Surgery, 2003
Myobloc, known as Neurobloc in Europe, is a member of the botulinum toxin family. It has been used for a myriad of problems since its approval in the United States in December 2000. It is currently not approved for cosmetic use but has been used for this purpose. This article reviews what is currently known about botulinum toxin type B and its efficacy
Leslie, Baumann, Laura, Black
openaire   +2 more sources

Botulinum Toxin Type A in Dental Medicine

Journal of Dental Research, 2019
Botulinum toxins (BoNTs) are a product of the bacteria Clostridium botulinum. By entering nerve endings, they cleave and inactivate SNARE proteins, which are essential for neurotransmitter release. Prevention of acetylcholine release at the neuromuscular junction causes long-lasting and potentially fatal flaccid paralysis—a major feature of botulism ...
V.R.M. Muñoz Lora, A.A. Del Bel Cury, B. Jabbari, Z. Lacković   +3 more
openaire   +2 more sources

Botulinum toxin type A in chronic migraine

Expert Review of Neurotherapeutics, 2007
The use of botulinum toxin type A continues to be investigated by the US FDA for potential use in the treatment of headache. As part of this process there has been extensive research conducted by individual study sites as well as multicenter trials. To date, the majority of the focus has been on migraine headache as well as on tension-type headache ...
openaire   +2 more sources

Botulinum Toxin Type A for Chronic Migraine

Current Neurology and Neuroscience Reports, 2010
Chronic migraine (CM) is the leading cause of chronic daily headache, a common and debilitating headache syndrome. The management of CM patients is challenging, with only limited benefit from available oral preventive medications. Botulinum neurotoxin (BoNT) has been used extensively to treat disorders associated with increased muscle tone. More recent
openaire   +2 more sources

Detoxification of Crystalline Botulinum Type A Toxin

The Journal of Immunology, 1947
Summary Botulinum Type A toxoid has been prepared from crystalline toxin by the addition of formaldehyde. The most active preparation consisted of one component electrophoretically, immunized mice in a dose containing 0.01γ of toxoidnitrogen and was 2400 times more active antigenically than crude toxoid on the basis of nitrogen-content.
G A, HOTTLE, A, ABRAMS
openaire   +2 more sources